Johnson & Johnson
13F holdings for Q2 2026 · NEW BRUNSWICK, NJ · filed August 6, 2026
Johnson & Johnson reported $799M in 13F securities across 15 holdings for Q2 2026, in a Form 13F filed August 6, 2026. The largest positions were PTGX (37.6%), NBTX (26.5%), Meiragtx Holdings PLC (11.2%). Reported value rose 22.4% from the quarter before. It opened 1 new position, added to 0, trimmed 0 and sold out of 2.
- 13F value Q2 2026
- $799M
- Holdings
- 15
- Change vs prior quarter
- +22.4%
- Rank by 13F value
- #2,923
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Top holdings
| Stock | Value | Weight | Shares | Change in shares | Move |
|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics Inc. | $300M | 37.6% | 2,449,183 | 0% | Unchanged |
| NBTX Nanobiotix S.A. | $212M | 26.5% | 5,623,816 | 0% | Unchanged |
| Meiragtx Holdings PLC | $89.7M | 11.2% | 6,641,064 | 0% | Unchanged |
| RAPP Rapport Therapeutics Inc. | $74.4M | 9.3% | 1,784,517 | 0% | Unchanged |
| CTNM Contineum Therapeutics Inc. | $32.4M | 4.1% | 1,979,173 | 0% | Unchanged |
| LEGN Legend Biotech Corporation | $23.5M | 2.9% | 814,586 | 0% | Unchanged |
| CVRX CVRx Inc. | $20.7M | 2.6% | 4,024,861 | 0% | Unchanged |
| XNCR Xencor Inc. | $12.0M | 1.5% | 748,062 | 0% | Unchanged |
| CBRS Cerebras Systems Inc. | $11.8M | 1.5% | 53,586 | New | New |
| FATE Fate Therapeutics Inc. | $9.1M | 1.1% | 3,379,064 | 0% | Unchanged |
| PRCT PROCEPT BioRobotics Corporation | $8.1M | 1.0% | 357,939 | 0% | Unchanged |
| NMRA Neumora Therapeutics Inc. | $3.1M | 0.4% | 1,849,445 | 0% | Unchanged |
| VOR Vor Biopharma Inc. | $989K | 0.1% | 53,732 | 0% | Unchanged |
| LAB Standard BioTools Inc. | $257K | 0.0% | 311,967 | 0% | Unchanged |
| ACET Adicet Bio Inc. | $197K | 0.0% | 22,779 | 0% | Unchanged |
Share positions only, at the value reported for the end of Q2 2026. Weight is the share of $799M in share positions; options and bonds count in the 13F value but not here.
Biggest buys in Q2 2026
- CBRS Cerebras Systems Inc. New+$11.8M
Biggest sells in Q2 2026
- RLYB Rallybio Corporation Sold out-$1.4M
- Nano X Imaging LTD Sold out-$190K
The change in shares since Q1 2026, adjusted for stock splits and priced at the Q2 2026 value per share. 1 new, 0 added, 0 trimmed, 2 sold out.
Sector mix
- Health Care87.3%
- Not listed with us11.2%
- Technology1.5%
- Industrials0.0%
13F value by quarter
Questions about Johnson & Johnson
- What does Johnson & Johnson own?
- In its Form 13F for Q2 2026, Johnson & Johnson reported 15 holdings worth $799M. The five largest were PTGX, NBTX, Meiragtx Holdings PLC, RAPP, CTNM.
- What did Johnson & Johnson buy and sell in Q2 2026?
- Johnson & Johnson opened 1 new position, added to 0, trimmed 0 and sold out of 2 compared with the quarter before.
- When did Johnson & Johnson file its latest 13F?
- Form 13F is due 45 days after each quarter ends. The Q2 2026 report was due August 14, 2026 and was filed August 6, 2026.
From Form 13F filed by Johnson & Johnson (SEC CIK 0000200406) for the quarter ended June 30, 2026, via the SEC's Form 13F data sets. Amendments that restate a report replace it; amendments that add holdings are included. View on SEC EDGAR · All funds